Impact of SGLT2 Inhibitors on QTc Interval and Arrhythmia Burden in Patients With Diabetes and Heart Failure: A Systematic Review and Meta-Analysis
Abstract
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated substantial benefits in reducing hospitalization for heart failure and cardiovascular mortality in patients with type 2 diabetes and heart failure. However, their electrophysiologic effects remain poorly characterized. QTc prolongation and arrhythmia burden are clinically important safety endpoints that influence therapy selection, especially in high-risk heart failure populations. While SGLT2i are widely used, few studies have synthesized their effects on QTc interval and arrhythmia outcomes.
Start Time
15-4-2026 1:30 PM
End Time
15-4-2026 4:30 PM
Room Number
Culp Ballroom 316
Poster Number
34
Presentation Type
Poster
Presentation Subtype
Posters - Competitive
Presentation Category
Health
Student Type
Graduate and Professional Degree Students, Residents, Fellows
Faculty Mentor
Manar Jbara
Impact of SGLT2 Inhibitors on QTc Interval and Arrhythmia Burden in Patients With Diabetes and Heart Failure: A Systematic Review and Meta-Analysis
Culp Ballroom 316
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated substantial benefits in reducing hospitalization for heart failure and cardiovascular mortality in patients with type 2 diabetes and heart failure. However, their electrophysiologic effects remain poorly characterized. QTc prolongation and arrhythmia burden are clinically important safety endpoints that influence therapy selection, especially in high-risk heart failure populations. While SGLT2i are widely used, few studies have synthesized their effects on QTc interval and arrhythmia outcomes.
